Channel 4 promised to ask whether ADHD is a genuine neurodevelopmental disorder or a social construct. It asked some important questions. The problem is that several of its most memorable answers were supported by evidence that could not bear their weight.

I went into The Great ADHD Myth? wanting it to be good.

There is a serious programme to be made about ADHD. Diagnostic thresholds deserve scrutiny. Private provision deserves scrutiny. Children’s exposure to psychoactive medication deserves particularly careful scrutiny. Schools can disable some children by the way they are organised. Screens, sleep, exercise, diet and family circumstances matter. Pharmaceutical companies have commercial interests. People can be misdiagnosed. Medication can cause harms as well as benefits.

None of that is heresy. Much of it is ordinary good medicine.

But Channel 4 set itself a larger task. Its own publicity asked whether ADHD is a genuine neurodevelopmental disorder or a social construct, and whether modern life might instead explain the behaviours we call ADHD.¹ By the end, Max Pemberton’s answer was substantially that we have mistaken a socially produced problem for a disorder of the brain.

That is an empirical claim. It needs evidence capable of distinguishing those explanations.

The documentary did not provide it.

First, separate the claims

The programme repeatedly moved between propositions that sound related but are not interchangeable:

• ADHD traits exist on a continuum.
• There is no brain scan that can diagnose ADHD in an individual.
• Diagnostic thresholds involve clinical judgement.
• Some people may be diagnosed incorrectly.
• Commercial incentives may distort some private assessments.
• Modern environments can increase impairment.
• Medication can make some children feel less like themselves.
• Medication can make children easier to teach.
• ADHD is therefore not a neurodevelopmental disorder.
• Medication therefore treats social inconvenience rather than an underlying disorder.

The first seven can all be true without the last two following.

This is the documentary’s recurring logical problem. Evidence for a narrow proposition is repeatedly allowed to cast suspicion on a much broader one. The programme is strongest when it asks whether our diagnostic and treatment systems sometimes fail children. It is weakest when those failures are presented as evidence that the phenomenon being diagnosed is itself socially invented.

The brain-scan test tests the wrong thing

Professor Katya Rubia’s contribution is important. Structural and functional neuroimaging findings in ADHD are subtle, heterogeneous and heavily overlapping with people without the diagnosis. There is no MRI pattern that can tell a clinician whether the person sitting in front of them has ADHD. That is worth saying loudly.

But “there is no diagnostic brain scan” and “there is no neurodevelopmental disorder” are entirely different propositions.

Large imaging studies have reported small average differences in children with ADHD, including cortical surface area and several subcortical structures, while also finding that those effects diminish with age and are nowhere near specific enough for individual diagnosis.² The honest conclusion is therefore modest: neuroimaging does not currently diagnose ADHD, and simplistic pictures of an “ADHD brain” should be treated sceptically.

That does not establish the programme’s larger alternative.

Many medical and psychiatric conditions are clinical constructs whose biology is probabilistic rather than individually diagnostic. More importantly, the category “neurodevelopmental” does not require a visible lesion on an MRI. The programme sets up a test that the mainstream clinical account does not require ADHD to pass, then treats failure of that test as evidence against the account.

That is a straw man dressed as a scan.

Pemberton’s diagnosis does not show that a diagnosis can be bought

Pemberton undergoes a private assessment costing £1,200. It includes pre-assessment questionnaires, collateral childhood information from a relative and a 90-minute clinical interview. He is diagnosed with combined-type ADHD and offered lisdexamfetamine. He does not believe the diagnosis.

It is an arresting piece of television. It is not, by itself, a validation study.

To demonstrate a false-positive diagnosis, the programme needs some independent reason to know that Pemberton does not meet diagnostic criteria. His conviction that he does not have ADHD is not that standard. Nor is professional success. Nor is the fact that many viewers might recognise some of the traits he described.

The clinically interesting question is impairment. NICE does not recommend diagnosing ADHD because someone occasionally interrupts, loses things or squirms. Diagnosis requires a specialist assessment, developmental and psychiatric history, symptoms occurring often in multiple important settings and clinically significant impairment; rating scales alone are insufficient.³

If Pemberton gave a truthful history but the clinician inferred impairment that was not there, that is a legitimate criticism of the assessment. If important differential diagnoses were ignored, likewise. If he presented a deliberately distorted history, the experiment tests something different again: whether a medically knowledgeable person can deceive an assessor.

The programme never establishes a gold standard against which its headline result can be judged. One disputed diagnosis can illustrate diagnostic uncertainty. It cannot estimate the false-positive rate of private ADHD practice, still less show that “if you want the diagnosis, you will be able to get it”.

That broader private-market question matters enormously. The 2023 BBC Panorama investigation documented examples of assessments that specialists considered inadequate, and the Royal College of Psychiatrists subsequently acknowledged genuine quality concerns while also emphasising the desperation created by very long NHS waits.⁴ The right conclusion is that assessment quality needs regulation and audit. It is not that paying privately makes the resulting diagnosis presumptively false.

The medication “experiment” is worse than anecdote

Pemberton then takes lisdexamfetamine.

As evidence about the therapeutic effects of optimised stimulant treatment in ADHD, calling this an anecdote is almost too generous.

It is a knowingly expectancy-laden exposure by a participant who rejects the diagnosis, undertaken while making a television documentary about whether the diagnosis and treatment are misguided. There is no placebo comparator, no blinding, no meaningful baseline, no standardised outcome, no independent observer, no replication and — crucially — no ordinary process of dose optimisation against benefit and adverse effects.

He feels quieter, less sociable, less curious and irritated by the crew. Those experiences are real. If a patient told me that treatment made them feel less recognisably themselves, I would regard that as clinically important. Treatment is not successful merely because somebody sits still.

But the inference has to stop there.

NICE explicitly describes titration as adjusting dose against symptoms and adverse effects until there is reduced impairment and improvement in education, employment or relationships with tolerable adverse effects.⁵ Modern trial evidence is not based on a journalist taking a tablet on camera: randomised controlled evidence across thousands of participants finds average short-term benefit from stimulant medication, alongside adverse effects and important limitations in the long-term evidence.⁶

Most strikingly, a 2026 dose-effect network meta-analysis of 113 randomised trials specifically examined how efficacy and tolerability change with dose.⁷ That is what a therapeutic dose question looks like scientifically.

Pemberton’s experience is useful testimony about how one person felt on a drug. It is almost maximally uninformative as an experiment capable of adjudicating whether appropriately diagnosed people benefit from properly titrated treatment.

Mason is not an experiment either — and that matters more

The emotional centre of the programme is Mason, a ten-year-old who has taken ADHD medication for two years and says it takes his “fun-ness” away.

His concern deserves more respect, not less, because he is a child. The programme is right to ask a profoundly uncomfortable question: are we treating a child for the child’s benefit, or because medication makes that child easier for adults and institutions to manage?

Whether medication allows a child to flourish or merely makes that child easier for adults to manage is a question medicine should never stop asking.

But asking it does not establish that the child’s underlying difficulty was invented by the adults around them.

Mason stops medication for six weeks. At the same time, screens are removed, diet is changed, outdoor and sporting activity increases, yoga is introduced, his family’s attention to the project necessarily changes and a television crew is documenting the process. By week three he appears happier and more animated. His mother sees more of the son she recognises. His social life seems better. School, however, becomes harder: concentration and disruption worsen. Before medication his mother describes marks of two or three out of sixty; on treatment, she says he had reached the expected level for his peers.

So what caused what?

The design cannot tell us. Medication withdrawal, screen restriction, diet, exercise, yoga, expectation, maturation, family attention and filming all move together. There is one child, no control, no blinding and no way to separate components. If the question is “can this family learn something useful by trying a supervised medication break?”, the answer may be yes. If the question is “does this show that lifestyle treats the real cause of ADHD?”, the answer is no.

And Mason’s mixed outcome is actually more interesting than the programme’s preferred narrative. Happier but learning less well is not “better”. Easier to teach but feeling unlike yourself is not “better” either. Those are competing outcomes that require the child, family and clinicians to decide what matters, review treatment and revisit that decision over time.

That is already how good ADHD care is supposed to work. NICE recommends environmental modifications before medication in children aged five and over, and medication only where significant impairment persists; it also recommends regular review including the child or young person’s preference, benefits, adverse effects, educational impact and periods of no treatment.⁸

Some claims needed a red pen

Beyond the central experiments, the programme contains assertions that deserved much harder interrogation.

Dr Iona Heath looks at symptom descriptions including squirming, waiting one’s turn and playing quietly and asks, in effect, how such ordinary behaviours can define disease. The rhetorical force comes from stripping symptoms away from the diagnostic rules surrounding them. “Often unable to play quietly” is not “does not always play quietly”. More importantly, the individual symptom is not the diagnosis. Frequency, persistence, developmental history, cross-situational presence, impairment and differential diagnosis are doing the clinical work.³

The “what’s the unit of squirm?” line is clever television. It is not a serious objection to clinical measurement. Pain has no blood-test unit either. Neither does delirium, depression or capacity. Medicine routinely measures latent constructs imperfectly using history, observation, validated instruments, function and longitudinal change. The relevant question is whether those measurements are reliable and useful enough — not whether squirming can be expressed in millimoles per litre.

Claims linking sugar directly to ADHD also require qualification. Diet matters to health, and selected elimination diets may help a subgroup of children, but systematic reviews have not found evidence supporting elimination of sucrose or aspartame as an ADHD treatment.⁹ Screens are similarly plausible modifiers of sleep, attention and behaviour, but association, bidirectional causation and underlying attentional traits are difficult to disentangle. “Modern life can worsen attention” is not evidence that modern life created ADHD.

Then there is the language: “chemical cosh”, comparisons with cocaine, “playing around with brain chemistry”, medication as behavioural control, and the suggestion that corporal punishment has been replaced by pharmacological discipline. These are not neutral descriptions awaiting evidence. They are moral frames. Sometimes a moral frame is justified. But when the programme repeatedly demands mechanistic certainty from the conventional account while permitting dramatic analogy on the sceptical side, the asymmetry becomes editorial rather than scientific.

Who is speaking — and what did viewers need to know?

Expertise matters. So does intellectual history.

Dr Sami Timimi is not simply a child psychiatrist who happened, on this occasion, to reach a sceptical conclusion about ADHD. He has argued for more than two decades that ADHD is best understood as a cultural construct, has written on the “medicalisation of naughty boys”, has questioned the validity of adult ADHD and has advocated non-diagnostic approaches to child mental health.¹⁰ That does not make him wrong. It makes his longstanding theoretical position relevant context when his authority is used to support the programme’s thesis.

The same principle applies to Pemberton. Before making this documentary he had publicly described adult ADHD as a “new craze”, private assessment as a “gold mine” and ADHD as wildly overdiagnosed.¹¹ Again, prior belief is not disqualification. Investigative journalism often starts with a hypothesis. The safeguard is transparency and active attempts to disconfirm it.

Dr Iona Heath is introduced with the considerable authority of a former president of the Royal College of General Practitioners. Before broadcast, Channel 4 publicity quoted her saying that ADHD is “certainly not a medical condition as far as I’m concerned”. The RCGP took the unusual step of publicly distancing itself from that statement, making clear that she was not speaking on its behalf and that the College recognises ADHD as a neurodevelopmental condition and supports evidence-based care.¹²

That distinction matters. “Former president of the RCGP” tells the viewer why someone is authoritative. It can easily be heard as institutional weight. If the institution itself says the quoted view is not its position, that is relevant editorial context.

Professor Dinesh Bhugra’s description of an ADHD “industry” making money “at the cost of the misery of others” is similarly powerful because it comes from a former president of the Royal College of Psychiatrists. Commercial incentives in private medicine are a legitimate subject of investigation. But prestige is not data. How large is the problem? Which providers? What diagnostic rates would be expected in a highly selected referred population? How often are assessments rejected after independent review? Those are answerable questions. The programme too often substitutes an eminent person saying something memorable for answering them.

The editorial argument is bigger than any individual claim

No documentary is neutral. Selection, sequencing, music, imagery, narration and juxtaposition are arguments.

Here the cumulative argument is clear. ADHD is introduced through doubt. Diagnostic criteria are made to look absurd by reading ordinary behaviours without their thresholds. Brain imaging is asked to provide an individual biological signature it cannot provide. Pemberton receives a diagnosis he does not believe and medication he dislikes. A child becomes more animated after medication withdrawal. Sceptical contributors invoke social control, pharmaceutical profit and chemical suppression. Medication is linguistically associated with amphetamines, cocaine, altered personality and the disciplining of children.

None of those components is illegitimate to include. Together they create a burden of proof problem.

The conventional account is repeatedly required to prove specificity: show me the scan, show me the biological lesion, prove the diagnostic boundary, prove long-term benefit. The alternative account is permitted much looser evidence: one family changing six things at once, an adverse medication experience, broad observations about modern childhood, expert opinion and rhetorical analogy.

If the thesis is that ADHD is socially constructed, that thesis also needs to survive causal scrutiny. What prospective evidence shows that screens or school structures generate the developmental phenotype? Why do similar traits appear across cultures and before smartphones? How should heritability be interpreted? Why do symptoms persist in adults whose environments differ radically from classrooms? What evidence distinguishes social causation from social modulation of impairment?

The programme is much better at cross-examining the medical model than cross-examining its replacement.

A false dichotomy survives the entire programme

The deepest problem remains the one with which this series began: neurodevelopment and social context are presented as rivals.

They are not.

A trait can be substantially heritable and environmentally modulated. A neurodevelopmental difference can become disabling in one environment and relatively inconsequential in another. Schools can be redesigned to accommodate variation without implying that every child’s difficulties were manufactured by school. Medication can improve executive function while environmental changes reduce the amount of executive function demanded. A diagnostic threshold can be socially negotiated while the underlying trait distribution remains biologically influenced.

In fact, NICE guidance already explicitly recommends environmental modifications and recognises that symptoms and impairment change with context.¹³ The choice is not “change the child” or “change society”. Good care can do both, neither, or different amounts of each according to the person in front of us.

What is television doing to ADHD?

This is Channel 4’s second major ADHD documentary in little over a year. In 2025, Do You Have ADHD? was commissioned to show viewers the stages of assessment, “separate fact from fiction” and explore life after diagnosis.¹⁴ Its very premise sat rather differently from this programme’s.

Then there is the BBC’s 2023 Panorama: Private ADHD Clinics Exposed. That investigation asked a legitimate and narrower question: were some private clinics diagnosing and prescribing without adequate assessment? It produced examples of concerning practice. It also attracted substantial criticism for its design, comparison of private assessments with an unusually extensive NHS assessment, and the risk of generalising from selected clinics to private ADHD care as a whole.⁴

There is a pattern here. ADHD is extraordinarily television-friendly. There are enormous waiting lists, controlled drugs, children, private money, disputed boundaries, charismatic experts and people who can be filmed before and after an intervention. The subject contains genuine uncertainty and genuine failures. It also contains everything required for a culture-war format.

The danger is that television turns epistemic uncertainty into a sequence of stunts. Can a reporter obtain a diagnosis? What happens if a child stops medication? What happens when the presenter takes a stimulant? These are compelling scenes. They are also very poor substitutes for prevalence studies, blinded trials, longitudinal cohorts, diagnostic-validation work and careful qualitative research.

Television can add something valuable when it makes those dry questions human. It becomes harmful when the human story is made to answer the scientific question by itself.

Why the editorial standard matters

This is not merely an argument about whether Channel 4 was fair to a diagnostic label.

People make healthcare decisions in the world created by programmes like this. Parents may decide whether to let a child try medication. Adults may decide whether years of difficulty justify seeking assessment. Teachers interpret behaviour. GPs decide how comfortable they feel continuing treatment initiated elsewhere. Employers decide whether an accommodation reflects disability or fashion. Friends and relatives decide whether someone’s diagnosis is an explanation or an excuse.

Overdiagnosis has harms. So does underdiagnosis. Inappropriate medication has harms. So does withholding effective treatment. A commercial market can exploit desperate patients. Public scepticism can also leave genuinely impaired people waiting years because their condition has been reframed as poor parenting, excessive TikTok or an inability to tolerate ordinary life.

That is why “we are only asking questions” is not enough. The more authoritative the broadcaster and contributors, the greater the obligation to show viewers which questions the evidence can actually answer.

Where I land

I have skin in this argument, but that is precisely why I do not want an article that simply defends ADHD.

I think some people are probably diagnosed who should not be. I think commercial incentives deserve investigation. I think diagnostic criteria require judgement rather than discovering a natural line in the population. I think childhood medication deserves unusually careful consent, review and attention to the child’s own experience. I think we should change schools, workplaces and homes where relatively simple changes allow people to function without treatment. I think we should be much more interested in sleep, exercise, distraction, trauma, anxiety, grief and the other things that alter attention and executive function.

I also think none of that requires pretending that neurodevelopment stops existing when context matters.

My own diagnosis came after an established professional career. On a superficial reading, that could be offered as evidence that the diagnosis must therefore be unnecessary: if someone can achieve difficult things, how impaired can they really be? My experience is almost the opposite lesson. External achievement is a poor measure of the effort, compensation and vulnerability underneath it. Treatment has not made me quieter, more compliant or more willing to sit through boring meetings. Properly titrated stimulant treatment has reduced the amount of cognitive effort required to do things I was already trying to do.

That is also only one person’s experience. I would object just as strongly if somebody used it to prove that stimulants work wonderfully for everyone.

The point is methodological as much as personal: Mason’s experience matters. Pemberton’s experience matters. Mine matters. None of us is a randomised controlled trial.

So, did The Great ADHD Myth? make its case?

It made part of a case.

It made a case for taking children’s subjective experience of medication seriously. It made a case for looking harder at schools and environments before assuming every difficulty requires a prescription. It made a case for scepticism about commercial diagnostic markets and for demanding high-quality assessment. It reminded viewers that psychiatric diagnoses are clinical constructs rather than truths revealed by a scan. Those are useful contributions.

It did not demonstrate that ADHD is merely a social construct. It did not establish that private diagnosis can simply be bought. It did not show that lifestyle changes can substitute for medication generally. It did not show that stimulant medication merely suppresses normal personality. And it did not provide an evidential basis for moving from “there are problems with how ADHD is diagnosed and treated” to “the disorder itself is the myth”.

The frustrating thing is that the narrower documentary would have been the better one.

There is no need to choose between credulity and denial. We can demand better diagnoses without humiliating people who have them. We can demand better evidence for medication without treating pharmacology as moral contamination. We can redesign environments without denying neurodevelopment. We can investigate private clinics without assuming private patients are consumers purchasing an identity. And we can listen when a child says a medicine makes him feel less like himself while also caring that he is falling behind at school.

I hope that is where the public conversation goes next: away from whether ADHD is “real”, and towards the much harder questions of who is impaired, why, in which environments, what helps, what harms, and how we know.

---

Series disclosure: I am a doctor diagnosed with ADHD in adulthood and take lisdexamfetamine. This is context, not evidence; the clinical claims in this series should stand or fall on the sources cited.

Sources and further reading

• Channel 4’s own commissioning and publicity material for The Great ADHD Myth?.
• NICE guideline NG87, Attention deficit hyperactivity disorder: diagnosis and management.
• Large-scale ENIGMA neuroimaging studies of structural differences associated with ADHD.
• Cortese and colleagues’ network meta-analysis of ADHD medication efficacy and tolerability.
• Nourredine and colleagues’ 2026 dose-effect network meta-analysis.
• Royal College of General Practitioners statement on the Channel 4 documentary.
• Royal College of Psychiatrists response to Panorama: Private ADHD Clinics Exposed.
• Sami Timimi’s published work on ADHD as a cultural construct and non-diagnostic psychiatry.

Series navigation

← Previous: Article 1 — The problem begins with the question · Series index · Next: Article 3 — Neurodevelopment, biology and social context →